Novo Nordisk's anti-inflammatory drug fails to reduce cardiovascular risk in late-stage trial
The trial failure erased more than $30 billion in market value and raised doubts about Novo Nordisk’s plan to expand beyond Ozempic and Wegovy.
- On Friday, Novo Nordisk shares dropped 9.3% after the Danish drugmaker reported its experimental drug "did not achieve" primary cardiovascular goals, erasing more than $30 billion in market value.
- Jeffries analysts described the trial results as "strategically negative," noting ziltivekimab needed a 20% risk reduction and eliminating a growth opportunity worth more than $10 billion annually beyond Ozempic and Wegovy.
- Goldman Sachs analysts previously identified the drug as foundational for a cardiovascular franchise, while the stock's 9.3% drop marks its largest intraday loss since February, contributing to a 10.6% decline this year.
- Novo Nordisk has already introduced a Wegovy pill in the United Arab Emirates as it pivots to expand its GLP-1 market presence with alternative pill versions of its medications.
- Separately, Novo Nordisk clashed with Eli Lilly earlier this month, accusing the rival of "deceptive" advertising; Lilly refused to settle, calling its marketing "truthful" and "transparent" in court documents.
29 Articles
29 Articles
Novo Nordisk, the Danish pharmaceutical company that led the global market with its new obesity drug 'Wigovi,' has suffered another setback in the development of a new cardiovascular drug. As the company failed to meet key endpoints in late-stage clinical trials, market concerns are mounting regarding its growth strategy, which is heavily skewed toward obesity treatments. According to Novo Nordisk on the 31st (local time), the cardiovascular dis…
Ziltivekimab reduces inflammation, not MACE risk in patients with atherosclerosis, CKD
Ziltivekimab, a novel interleukin-6 inhibitor, reduced inflammatory markers in patients with atherosclerosis and chronic kidney disease but did not lower risk for major adverse CV events, according to results of the ZEUS CV outcomes trial. For the double-blind, placebo-controlled, phase 3 ZEUS trial, researchers enrolled more than 6,300 patients with atherosclerotic CVD, chronic kidney disease
The Danish pharmaceutical giant fails with its heart drug ziltive kimab in a pivotal study. It could have had a billion-dollar sales potential.
Coverage Details
Bias Distribution
- 59% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
